Human Longevity, Inc. (HLI) has partnered with Alamar Biosciences to incorporate ultra-sensitive proteomic testing into its longevity-focused clinical programs, aiming to enhance early disease detection and health monitoring.

This collaboration is designed to improve early detection of age-related diseases, particularly neurodegenerative conditions, by analyzing proteins associated with inflammation and brain health.

HLI will utilize Alamar’s NULISAseq Inflammation Panel 250 and CNS Disease Panel 120, which detect biomarkers linked to chronic inflammation and neurological health at attomolar sensitivity.

Earlier this month, Alamar partnered with the German Center for Neurodegenerative Diseases to analyze 23,000 plasma samples in the Rhineland Study, aiming to identify protein biomarkers that reveal mechanisms of healthy aging and disease progression.

HLI emphasizes that proteomics is a crucial frontier in longevity medicine, moving toward predictive and preventive healthcare by integrating protein data with other omics analyses.

The new proteomic panels will be integrated into HLI’s Executive Health and Longevity programs later this year, complementing existing genomics and imaging data collected from over 10,000 clients.

Both companies see this partnership as a major step forward in advancing healthy aging science and developing practical tools for longer, healthier lives.

Founded by J. Craig Venter, HLI combines diagnostics, AI, and personalized medicine, and has invested heavily in early cancer detection and treatment for its members.